Completed PHASE3 INTERVENTIONAL 5-arm NCT00743652

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children.

Sponsor: Pfizer

Conditions 13-valent Pneumococcal Vaccine Pneumococcal Disease

Interventions 13-valent Pneumococcal Conjugate Vaccine

Updated 7 times since 2017 Last updated: Mar 13, 2012 Started: Jan 31, 2009 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates 13-valent Pneumococcal Vaccine and Pneumococcal Disease and is currently completed. Pfizer leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akiak, United States , Bethel, United States , Chefornak, United States , Chevak, United States , Eek, United States , Emmonak, United States , Hooper Bay, United States , Kalskag, United States , Kasigluk, United States , Kongiganak, United States and 11 more locations